Demonstrated efficacy results in OCS dose compared to baseline dose in VENTURE*

Table outlining the oral corticosteroid reduction data in VENTURE. The mean percent reduction in daily OCS dose from baseline at Week 24 was 70.1% for DUPIXENT (median 100%) and 41.9% for placebo (median 50%). The percentage of patients with an OCS dose reduction of greater than or equal to 50% was 79.6% (n=82) for DUPIXENT and 53.3% (n=57) for placebo. The percentage of patients with a mean final OCS dose under 5 milligrams at Week 24 was 69% for DUPIXENT and 33% for placebo. The percentage of patients with 100% reduction in OCS dose was 52.8% for DUPIXENT (54 out of 103 patients) and 29.2% for placebo (31 out of 106 patients). “Patients with 100% reduction in OCS dose” is cross referenced to a footnote which states: “Only subjects with daily baseline OCS dose less than or equal to 30 mg were eligible to achieve a 100% reduction in OCS dose during the study.”
 

Annualized rate of severe exacerbation events (secondary endpoint)

Bar chart showing the annualized rate of severe exacerbation events in VENTURE, which was a secondary endpoint. The y-axis is the adjusted rate of severe exacerbations per year. The x-axis title is “Week 24”. The chart shows the data for DUPIXENT (n=103) and placebo (n=107). The adjusted rate of severe exacerbations per year was 1.60 for placebo and 0.65 for DUPIXENT.
Adapted from the Product Monograph.

Exacerbations were defined as an increase in oral corticosteroid dose for at least 3 days.

Demonstrated efficacy results in pre-bronchodilator FEV1 from baseline at Week 24 (secondary endpoint)1,3

In VENTURE, the LS mean change from baseline in pre-bronchodilator FEV1 at Week 24 was 0.22 L with DUPIXENT® vs. 0.01 L with placebo

FEV1=forced expiratory volume in 1 second; CI=confidence interval; LS=least squares; OCS=oral corticosteroid.
* Patients required at least 6 months of daily OCS (11.8 mg/day on average) in addition to regular use of high-dose inhaled corticosteroid (ICS) plus an additional controller.
† Only subjects with daily baseline OCS dose ≤30 mg were eligible to achieve a 100% reduction in OCS dose during the study.

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Freedom support program logo.

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.


Sanofi Regeneron Logo

DUPIXENT® (dupilumab injection) logo


DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300228
Last updated: 06/2023


Innovative Medicines Canada logo PAAB logo